Shares in Tokyo-listed Nxera Pharma slid 5% at market open after Boehringer walked away from the neurological assets.

In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...

Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

J&J has received the US FDA approval for Rybrevant Faspro, a SC administered therapy to treat patients with EGFR-mutated ...

The MHRA has launched a call for evidence seeking input from healthcare providers, the public, and health experts on AI ...

The EC has approved Incyte’s Minjuvi (tafasitamab) with lenalidomide and rituximab for adults with relapsed or refractory FL.

FREWITT S.A. located in Fribourg, Switzerland, and DEVA HOLDING A.S., located in Istanbul, Turkey are pleased to announce DEVA’s ...

Targeted patient recruitment can increase the likelihood of trial success and help cultivate use of precision medicine.

Poised to become law, the BIOSECURE Act will have ramifications for certain US-China pharmaceutical relationships.

Harbour BioMed and Bristol Myers Squibb (BMS) have signed a multi-year, worldwide strategic partnership and licence agreement ...

Propelled by a flurry of dealmaking late in the year, 2025 M&A ended on a strong note, with high activity expected to ...

The US Food and Drug Administration has approved Acadia Pharmaceuticals’ Daybue Stix (trofinetide), a dye and ...